1. In Vivo
  2. >>Archive

Merck's Vaccines: Why the Company's Down, but Definitely Not Out

Given it's late-stage pharma failures, Merck now finds itself importantly dependent on its vaccine pipeline--the majority of its phase III projects. Its commitment to innovation and willingness to self-fund large programs created major vaccines with drug-like potential, and little competition, itself a hallmark of the business to which Merck, and few other companies, has remained loyal. But the costs and risks of the program raise questions as to its long-term viability at a time when Merck's profits are under increasing pressure.

When Merck & Co. Inc. moved in 1992 into its gleaming new headquarters, hidden in the woods of rural Whitehouse Station, NJ, it seemed bravely symbolic—the company had never seen itself as part of the hurly-burly of the rest of the pharmaceutical industry. It went its own way, strategically and scientifically, and had rewarded shareholders with years of double-digit returns.

But as Merck's business has fallen on increasingly hard times, the isolation of the Whitehouse Station headquarters now seems more ominously symbolic of a company that didn't see competition coming,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.